Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.
In a recent study, a novel combination of treatments was discovered to effectively reduce the growth of pancreatic cancer in mice by inhibiting cancer cells from seeking fuel sources.
RNA molecules can undergo chemical changes like m6A, which can have a significant influence on gene expression and affect several aspects of cancer development and progression
A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the tumor microenvironment during gastric cancer progression.
Discussions of cancer often stress the genetic mutations that drive disease by altering the normal function of cellular proteins.
Scientists from the University of California, Irvine, the University of Michigan and the University of Texas MD Anderson Cancer Center have made a significant contribution to the field of pancreatic cancer research.
A new research paper was published in Genes & Cancer on March 10, 2023, entitled, "VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer."
A small but significant metabolic difference between human and mouse lung tumor cells, has been discovered by Weill Cornell Medicine researchers, explaining a discrepancy in previous study results, and pointing toward new strategies for developing cancer treatments.
A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Scientists from the University of California, Irvine, have defined how the circadian clock impacts cell growth, metabolism, and tumor progression in a new study.
A discovery regarding how a particular protein is triggered in tumor cells, conducted by researchers at the University of California, Irvine, may lead to more effective therapies for some of the deadliest types of cancer.
Drug resistance is a major obstacle in the treatment of cancers. In an aggressive type of pancreatic cancer, for instance, drug resistance is associated with the suppression of programmed cell death, which results in the uncontrolled growth of cancer cells.
Lung cancer is the second leading cancer in the United States and the No. 1 cause of cancer-associated deaths.
Scientists have homed in on a crucial step within the sequence of chemical reactions that govern regulation of cell division, proliferation and death, and whose malfunction contributes to the growth of tumors.
Researchers generated a 3D pancreatic cancer tumor model in the lab, merging a bioengineered matrix and patient-derived cells.
MIT engineers, in collaboration with scientists at Cancer Research UK Manchester Institute, have developed a new way to grow tiny replicas of the pancreas, using either healthy or cancerous pancreatic cells.
Lung cancer remains the leading cause of cancer-associated death in the United States and worldwide. Patients with a subtype called lung adenocarcinoma (LUAD) have benefited from the development of new targeted medicines, but the search for effective new therapies for another subtype called lung squamous cell carcinoma (LSCC) has largely come up short.
For many years, computer models have been standard tools in fundamental biomedical research.
By 2030, pancreatic ductal adenocarcinoma (PDAC), the most lethal form of pancreatic cancer, is projected to become the second leading cause of cancer-related deaths in the United States.
A study headed by UCM reports that polymorphisms in gene TGFB1 and low plasma levels of protein TGFB1 serve as biomarkers for the gastric adenocarcinoma prognosis.
Pancreatic cancer cells avert starvation by signaling to nerves, which grow into dense tumors and secrete nutrients. This is the finding of a study with experiments in cancer cells, mice, and human tissue samples published online on November 2 in Cell.